Correction: Jazz Pharmaceuticals initiates Erwinaze trial, says Brean Capital Jazz announced initiated its new clinical trial for Erwinaze with will evaluate intravenous administration in patients with ALL as an alternative to intramuscular injection. Brean Murray maintains its estimates but believes there could be upside to its 2014 forecast. Shares are Buy rated with an $81 price target.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Jazz Pharmaceuticals price target raised to $130 from $110 at UBS UBS raised its price target on Jazz Pharmaceuticals to adjust its discount rate to reflect a change in risk premium. The firm notes the company's business continues to perform above expectations and expects additional business activities to diversify the company. Shares are Buy rated.